What is the significance of this filing being an amendment (10-Q/A)?

An amendment to a 10-Q filing indicates that the company is correcting or supplementing information that was previously filed. Investors should scrutinize the amendments to understand what was changed and why, as it could impact previously reported financial data or key disclosures.

What period does this filing cover, and when was it filed?

This amended filing covers the period ending March 30, 1999, and was filed on July 15, 1999. The gap between the period end and filing date, especially for an amendment, suggests a need for careful review of the content.

Where can I find the detailed financial statements and operational information within this filing?

The provided excerpt is a directory listing and does not contain the detailed financial statements or narrative sections of the 10-Q/A. To access the full report, you would typically need to navigate to the 'txt' or 'htm' files associated with this filing on the SEC's EDGAR database.

What kind of information should investors look for in this 10-Q/A filing?

Investors should look for updates on revenue and earnings for the first quarter of 1999, changes in operating expenses, any new product development updates or regulatory news, and importantly, the specific nature of the amendments made to the original filing. This includes any restatements of financial data or clarifications of previously disclosed information.

LLY 10-Q Quarterly Report Q1 FY1999 — Revenue, Net Income, EPS

Summary

Eli Lilly and Company's (LLY) amended 10-Q filing for the period ending March 30, 1999, provides an update on its financial performance and operational activities. As an amendment, it suggests that the original filing may have contained errors or omissions that have since been corrected. Investors should pay close attention to the nature of the amendments to understand any potential impact on previously reported figures or disclosures. This filing is crucial for understanding the company's financial health and strategic direction in early 1999. While specific financial details are not provided in the excerpt, the amendment highlights the importance of accurate and timely reporting. Investors should look for any disclosed changes in revenue, earnings, debt, or significant business events that might have been restated or clarified in this amended filing.

Key Highlights

1Filing is an amendment (10-Q/A) to a previous quarterly report, indicating potential revisions to earlier disclosures.
2Period ending: March 30, 1999.
3Filed on: July 15, 1999, suggesting a delay or correction process.
4The document is a routine quarterly filing, essential for tracking short-term performance.
5Focus on the pharmaceutical sector, a critical industry with significant regulatory oversight.
6Information likely pertains to the first quarter of 1999.
7Investors should carefully review any changes from the original filing to understand the rationale and impact of the amendments.

ELI LILLY & Co Quarterly Report (Amendment) for Q1 Ended Mar 31, 1999

Summary

Key Highlights

Frequently Asked Questions